Key Insights

Highlights

Treatment Research

1 treatments under study, led by Ensartinib

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Unknown1
Not Yet Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT06780839Phase 2Not Yet RecruitingPrimary

Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD

NCT03509779UnknownPrimary

Pronostic and Predictive Value of EMT in Localized Lung Cancer

Showing all 2 trials

Research Network

Common Treatments

  • Ensartinib1

Active Sponsors

  • European Georges Pompidou Hospital1
  • Betta Pharmaceuticals Co., Ltd.1
  • APHP1
  • Peking University Cancer Hospital & Institute1

Top Investigators

Related Conditions

  • Epithelial Mesenchymal Transition1
  • Surgery1
  • Progression1

Activity Timeline